

Contact

www.linkedin.com/in/kridel
(LinkedIn)
www.ferghanapartners.com
(Company)

Top Skills

Leadership
Corporate Venture Capital
Going Public

Languages

French Spanish and others
English

Certifications

USA Supreme Court, 4 other federal courts, NY State courts, FINRA and PADI

William J Kridel Jr

Managing Director at Ferghana Partners
New York, New York, United States

Summary

Specialties: corporate partnering [inward and outward]; private placements and PIPEs; acquisitions and divestments; strategy...for biotech [product and technology], pharma and diagnostics companies in North America, Europe, Australia and Japan...India, Brazil and Argentina in JVs similar to those we set up in Israel and China

Experience

Kermode Biotechnologies

Director

February 2025 - Present (7 months)

United States

Company focused on providing cost-effective treatments for various communicable diseases affecting swine

Ferghana Partners

Managing Director & Founder

1991 - Present (34 years)

NYC, London, California

One30Seven Inc

Chairman

January 2024 - Present (1 year 8 months)

Kingston, Ontario, Canada

Provider of packaged and scalar equipment to render water soluble, radioactive isotopes [iodine. cesium, strontium etc], in waste, inert by application of proprietary technology built on high power laser-optics system for use by nuclear power plants, radiopharmaceuticals producers/users and military. Solves the nuclear waste problem which is a major political/social/environmental impediment to clean energy from nuclear power plants [new build or retrofit].

Gylden USA [sub of Gylden Pharma Ltd a/k/a Emergex Holding UK]

Chairman

April 2021 - Present (4 years 5 months)

United States

High science biotech company replying its proprietary technology and science insights behind targetable CD8+ T-cells for acute RNA based viral diseases such as Chikungunya, Ebola, Yellow Fever, Coronaviruses, Dengue, West Nile etc with delivery via a microarray patch with long life at room temperature and easy application: affordable cost for this immunotherapy with very long duration of effectiveness.

Triage Technologies Inc

Chairman

July 2024 - December 2024 (6 months)

Toronto, Ontario, Canada and USA

AI powered image analysis and identification of 577 dermatological conditions from images captured on a smartphone with very high accuracy in roughly 60 seconds. System approved Canada and EU and other markets [600M population] and planning for FDA approval program.

Trenchant Biosystems Inc

Director

May 2023 - December 2024 (1 year 8 months)

California, United States

creator of fully automated, high speed, desktop size cell production lab equipment capable of excellent quality CAR-T, TCR, CAR-NK and Stem Cells for client research and pharma clients: substantially lower cost capex/opex plus 3 day vein-to-vein turnaround time: resulting in greater patient access to these important therapies by decreasing the cost/price factor and by speeding up delivery due to co-location with patients [no complex and lengthy logistics].

Barclays de Zoete Wedd

Managing Director

December 1990 - September 1992 (1 year 10 months)

Peers & Co / Long Term Credit Bank of Japan

Managing Director; Chairman of Peers & Co International

January 1989 - December 1990 (2 years)

Paris

Kridel Group

Managing Director

1977 - 1988 (11 years)

Paris, New York, Abu Dhabi and Bermuda

Baring Brothers Ltd

Vice President

September 1971 - August 1976 (5 years)

London and Paris

Education

Columbia Law School

Doctor of Law (JD), International Law and Corporate Law · (1965 - 1968)

Yale University

BA, Political Science; Economics; Applied Behavioral Analysis · (1960 - 1964)